[Form 4] Sight Sciences, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sight Sciences (SGHT) Form 4: Chief Financial Officer Alison Bauerlein sold 19,260 common shares on 07/02/2025 at $4.098 per share. The transaction was flagged as a sale to cover taxes triggered by restricted stock unit (RSU) vesting, rather than a discretionary open-market trade. After the sale, Bauerlein still directly owns 617,468 shares, keeping the vast majority (≈97%) of her prior position and maintaining material skin in the game. No derivative transactions were reported. While any insider sale can draw scrutiny, the stated purpose and modest size relative to her holdings suggest limited fundamental impact. Investors may monitor future filings for additional activity but the current sale appears routine.

Insights

Financial Analyst

TL;DR: CFO sold 19k shares (≈3% of stake) for tax; minimal financial impact, neutral sentiment.

The 19,260-share disposition represents less than 0.1% of SGHT’s 61 million basic shares and roughly 3% of Bauerlein’s holdings. Proceeds (~$79k) are immaterial to corporate cash flows and were used to satisfy RSU tax withholding, a common administrative practice. Retention of 617k shares aligns the CFO with shareholder interests. Given the small scale and disclosed rationale, I classify the event as neutral with negligible influence on valuation or liquidity.

Corporate Governance Expert

TL;DR: Routine tax-withholding sale; insider retains large stake, governance risk low.

Rule 10b5-1 safe-harbor language is noted, reinforcing procedural compliance. The sale purpose—covering tax on RSU vesting—matches common governance practice and mitigates concerns of opportunistic timing. With over 600k shares still held, the CFO’s incentives remain aligned with shareholders. No red flags on control changes or undisclosed arrangements. Overall governance impact is immaterial.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bauerlein Alison

(Last) (First) (Middle)

C/O SIGHT SCIENCES, INC.

4040 CAMPBELL AVE., SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sight Sciences, Inc. [ SGHT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2025		S		19,260(1)	D	$4.098	617,468	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.

	/s/ Jeremy Hayden, Attorney-in-Fact for Alison Bauerlein	07/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.